IL4 and inflammatory breast carcinoma: Our in vitro data also showed that tumor Sdc-1 silencing did not significantly alter the proportion of the Th2 (IL4+CD4+) subset among CD4+ T cells of non-IBC patients under indirect and direct co-culture conditions.